Hematology

HR+

Questions discussed in this category

Would you use aspirin 81 mg for VTE prophylaxis in patients on adjuvant tamoxifen/SERMs?

Is there data that it actually helps?

1 Answer available

Do you discontinue anti-hormonal therapy if a high-risk ER+ HER2- localized breast cancer patient develops blood clots on anti-hormonal therapy?

How would you approach a patient who is intolerant of AI and develops thrombosis while on SERM?

3 Answers available

Papers discussed in this category

Lancet (London, England), 2014-03-22

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.

The New England journal of medicine, 2011-06-23

Exemestane for breast-cancer prevention in postmenopausal women.

Journal of the National Cancer Institute, 2005-09-07

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

The New England journal of medicine, 2016-07-21

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

J Natl Cancer Inst, 2011 Jul 09

Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.

Br J Clin Pharmacol, 2020 Jun 02

Effect of low-dose aspirin on health outcomes: An umbrella review of systematic reviews and meta-analyses.

Related Topics in Hematology